Please assess the completion status of the following clinical trial:

Trial Title: Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unresectable and/or metastatic, measurable renal cell carcinoma histologically or cytologically documented~* Patients must have had one prior systemic therapy for advanced disease, which was completed at least 30 days but no longer than 8 months prior to randomization~* Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST)~* Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1~* Patients who have adequate coagulation, liver and kidney functions~Exclusion Criteria:~* Patients with rare subtypes of renal cell carcinoma (RCC) such as pure papillary cell tumors, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors~* Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma,or superficial bladder tumors, or other malignancies curatively treated \> 2 years prior to entry~* Cardiac arrhythmias requiring anti-arrhythmics, symptomatic coronary artery disease or ischemia or congestive heart failure~* Patients with a history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C~* Patients with a history or presence of metastatic brain or meningeal tumors~* Patients with seizure disorder requiring medication (such as anti-epileptics)~* History of organ allograft or bone marrow transplant of stem cell rescue~* Patients who are pregnant or breast-feeding Women of childbearing potential must have a negative pregnancy test prior to drug administration. Both men and women enrolled in this trial must use adequate birth control~* Patients who have three or more of the following:~  * ECOG performance status greater than or equal to 2,~ * Abnormally high lactate dehydrogenase,~ * Abnormally high serum hemoglobin,~ * Abnormally high corrected serum calcium,~ * Absence of prior nephrectomy~* Excluded therapies and medications, previous and concomitant:~  * Concurrent anti-cancer chemotherapy, immunotherapy or hormonal therapy except biphosphonates~ * Significant surgery with 4 weeks of start of study~ * Investigational drug therapy during or within 30 days~ * Concomitant treatment with rifampin or St. John's Wort~ * Prior use of Raf-kinase inhibitors (RKI), MEK or Farnesyl transferase inhibitors~ * Prior use of Bevacizumab, and all other drugs (investigational or licensed) that target VEGF/VEGF receptors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Nexavar, BAY43-9006) (Type: EXPERIMENTAL): Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching in appearance were to be orally administered twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).